Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Yu-ling Si
Effects of the Proteasome Inhibitor Bortezomib in Combination With Chemotherapy for the Treatment of Mantle Cell Lymphoma: A Meta-Analysis
Turkish Journal of Haematology
Hematology
Related publications
Novel Chemotherapy-Free Combination Regimen for Ibrutinib-Resistant Mantle Cell Lymphoma
British Journal of Haematology
Hematology
Expanding Horizons in the Treatment of Mantle Cell Lymphoma: Ibrutinib a Novel BTK-targeting Inhibitor
International Journal of Basic & Clinical Pharmacology
Splenectomy in the Treatment of Mantle Cell Lymphoma
Hematology & blood transfusion: interdepartamental collection
Emerging Therapy for the Treatment of Mantle Cell Lymphoma
Journal of the National Comprehensive Cancer Network : JNCCN
Medicine
Oncology
Proteasome Inhibitor Bortezomib Modulates TLR4-induced Dendritic Cell Activation
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Bortezomib Prevents Development of Cytarabine Resistance in a Mantle Cell Lymphoma in Vitro Model
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Efficacy of Subcutaneous Bortezomib in the Management of Patients With Multiple Myeloma or Relapsed Mantle Cell Lymphoma
Clinical Medicine Insights: Therapeutics
Medicine
Pharmacology
Pharmaceutical Science
The Combination of the Proteasome Inhibitor Bortezomib and the BCL-2 Antisense Molecule Oblimersen Sensitizes Human B-Cell Lymphomas to Cyclophosphamide
Clinical Cancer Research
Cancer Research
Oncology
The Proteasome Inhibitor Bortezomib Interacts Synergistically With the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid to Induce T-Leukemia/Lymphoma Cells Apoptosis
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
